| Serial Number | 87765139 |
| Word Mark | EBI EXPONENTIAL BIOTHERAPIES |
| Filing Date | Monday, January 22, 2018 |
| Status | 700 - REGISTERED |
| Status Date | Tuesday, March 29, 2022 |
| Registration Number | 6681763 |
| Registration Date | Tuesday, March 29, 2022 |
| Mark Drawing | 3000 - Illustration: Drawing or design which also includes word(s) / letter(s) / number(s) |
| Published for Opposition Date | Tuesday, January 11, 2022 |
| Goods and Services | custom manufacture of medicines, pharmaceutical drugs, biopharmaceutical drugs, pharmaceuticals and biopharmaceuticals; treatment of biopharmaceutical and pharmaceutical materials being medicines, biopharmaceutical and pharmaceutical compounds, synthetic peptides and synthetic peptidomimetics; processing of medicines, biopharmaceutical and pharmaceutical compounds, synthetic peptides and synthetic peptidomimetics for others; custom manufacture of medical devices for others |
| Description of Mark | The mark consists of a broken circle comprised of a curved red band and a curved gray band. A red triangle appears in the middle of the left band and protrudes into the circle. Within the left side of the circle are two gray polygons of triangular shape with curved corners and lines. To the right of this circular design are the letters "EBI" appearing in a large gray font with the wording "EXPONENTIAL BIOTHERAPIES" appearing in a smaller gray font below. |
| Goods and Services | medicines, namely, medicines for alleviating or treating vasculogenic disease, medicines for alleviating or treating hemodynamic instabilities, medicines for alleviating or treating diabetes, medicines for alleviating or treating of immune system related diseases and disorders; pharmaceutical drugs, namely, pharmaceutical preparations for alleviating or treating vasculogenic disease, pharmaceutical preparations alleviating or treating hemodynamic instabilities, pharmaceutical preparations for alleviating or treating diabetes, pharmaceutical preparations for alleviating or treating of immune system related diseases and disorders; biopharmaceutical drugs, namely, biopharmaceutical preparations for alleviating or treating vasculogenic disease, biopharmaceutical preparations for alleviating or treating hemodynamic instabilities, biopharmaceutical preparations for alleviating or treating diabetes, biopharmaceutical preparations for alleviating or treating of immune system related diseases and disorders; biopharmaceuticals, namely, biopharmaceuticals for alleviating or treating vasculogenic disease, biopharmaceuticals alleviating or treating hemodynamic instabilities, biopharmaceuticals for alleviating or treating diabetes, biopharmaceuticals for alleviating or treating of immune system related diseases and disorders; synthetic peptides for biopharmaceutical purposes and for pharmaceutical purposes, namely, synthetic peptides for alleviating or treating vasculogenic disease, synthetic peptides for alleviating or treating hemodynamic instabilities, synthetic peptides for alleviating or treating diabetes, synthetic peptides for alleviating or treating of immune system related diseases and disorders; synthetic peptidemimetics for biopharmaceutical purposes and for pharmaceutical purposes, namely, sytnthetic peptidomimetics for alleviating or treating vasculogenic disease, synthetic peptidomimetics for alleviating or treating hemodynamic instabilities, synthetic peptidomimetics for alleviating or treating diabetes, synthetic peptidomimetics for alleviating or treating of immune system related diseases and disorders |
| Indication of Colors claimed | The red and gray are claimed as a feature of the mark. |
| Disclaimer with Predetermined Text | "BIOTHERAPIES" |
| Goods and Services | biopharmaceutical and pharmaceutical research; conducting clinical trials for others in the fields of medicines, synthetic peptides and synthetic peptidomimetics as they relate to use as an ingredient in medicines, biopharmaceuticals, pharmaceuticals, pharmaceutical drugs and biopharmaceutical drugs; scientific research of medicines, synthetic peptides and synthetic peptidomimetics as they relate to use as an ingredient in medicines, biopharmaceuticals and pharmaceuticals, pharmaceutical drugs and biopharmaceutical drugs; development, testing, and inspection of medicines, synthetic peptides and synthetic peptidomimetics as they relate to use as an ingredient in medicines, pharmaceutical drugs, biopharmaceutical drugs, pharmaceuticals and biopharmaceuticals; laboratory services relating to medicines, synthetic peptides, synthetic peptidomimetics, pharmaceutical drugs, biopharmaceutical drugs, pharmaceuticals and biopharmaceuticals, namely, research in the fields of medicines, synthetic peptides, synthetic peptidomimetics, biopharmaceuticals, pharmaceuticals, pharmaceutical drugs and biopharmaceutical drugs; laboratory analysis in the fields of medicines, synthetic peptides, synthetic peptidomimetics, biopharmaceuticals, pharmaceuticals, pharmaceutical drugs and biopharmaceutical drugs; medical research in the fields of medicines, synthetic peptides, synthetic peptidomimetics, biopharmaceuticals, pharmaceuticals, pharmaceutical drugs and biopharmaceutical drugs; scientific research for medical purposes in the fields of medicines, synthetic peptides, synthetic peptidomimetics, biopharmaceuticals, pharmaceuticals, pharmaceutical drugs and biopharmaceutical drugs |
| International Class | 005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides. |
| US Class Codes | 005, 006, 018, 044, 046, 051, 052 |
| Class Status Code | 6 - Active |
| Class Status Date | Friday, February 2, 2018 |
| Primary Code | 005 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| International Class | 040 - Treatment of materials. |
| US Class Codes | 100, 103, 106 |
| Class Status Code | 6 - Active |
| Class Status Date | Friday, February 2, 2018 |
| Primary Code | 040 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| International Class | 042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software. |
| US Class Codes | 100, 101 |
| Class Status Code | 6 - Active |
| Class Status Date | Friday, February 2, 2018 |
| Primary Code | 042 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| Party Name | Exponential Biotherapies, Inc. |
| Party Type | 30 - Original Registrant |
| Legal Entity Type | 03 - Corporation |
| Address | New York, NY 10017 |
| Party Name | Exponential Biotherapies, Inc. |
| Party Type | 20 - Owner at Publication |
| Legal Entity Type | 03 - Corporation |
| Address | New York, NY 10017 |
| Party Name | Exponential Biotherapies, Inc. |
| Party Type | 10 - Original Applicant |
| Legal Entity Type | 03 - Corporation |
| Address | New York, NY 10017 |
| Event Date | Event Description |
| Tuesday, March 29, 2022 | REGISTERED-PRINCIPAL REGISTER |
| Tuesday, January 11, 2022 | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED |
| Tuesday, January 11, 2022 | PUBLISHED FOR OPPOSITION |
| Wednesday, December 22, 2021 | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED |
| Tuesday, December 7, 2021 | LAW OFFICE PUBLICATION REVIEW COMPLETED |
| Thursday, December 2, 2021 | APPROVED FOR PUB - PRINCIPAL REGISTER |
| Thursday, December 2, 2021 | EXAMINER'S AMENDMENT ENTERED |
| Thursday, December 2, 2021 | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED |
| Thursday, December 2, 2021 | EXAMINERS AMENDMENT E-MAILED |
| Thursday, December 2, 2021 | EXAMINERS AMENDMENT -WRITTEN |
| Monday, November 29, 2021 | PREVIOUS ALLOWANCE COUNT WITHDRAWN |
| Tuesday, November 9, 2021 | WITHDRAWN FROM PUB - OG REVIEW QUERY |
| Monday, October 25, 2021 | LAW OFFICE PUBLICATION REVIEW COMPLETED |
| Saturday, October 16, 2021 | APPROVED FOR PUB - PRINCIPAL REGISTER |
| Wednesday, October 13, 2021 | TEAS/EMAIL CORRESPONDENCE ENTERED |
| Wednesday, October 13, 2021 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| Wednesday, October 13, 2021 | TEAS REQUEST FOR RECONSIDERATION RECEIVED |
| Tuesday, October 12, 2021 | NOTIFICATION OF FINAL REFUSAL EMAILED |
| Tuesday, October 12, 2021 | FINAL REFUSAL E-MAILED |
| Tuesday, October 12, 2021 | FINAL REFUSAL WRITTEN |
| Friday, October 1, 2021 | PREVIOUS ALLOWANCE COUNT WITHDRAWN |
| Friday, October 1, 2021 | WITHDRAWN FROM PUB - SENIOR ATTORNEY REQUEST |
| Friday, October 1, 2021 | APPROVED FOR PUB - PRINCIPAL REGISTER |
| Wednesday, September 1, 2021 | TEAS/EMAIL CORRESPONDENCE ENTERED |
| Wednesday, September 1, 2021 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| Wednesday, September 1, 2021 | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
| Monday, March 1, 2021 | NOTIFICATION OF NON-FINAL ACTION E-MAILED |
| Monday, March 1, 2021 | NON-FINAL ACTION E-MAILED |
| Monday, March 1, 2021 | NON-FINAL ACTION WRITTEN |
| Thursday, February 18, 2021 | TEAS/EMAIL CORRESPONDENCE ENTERED |
| Thursday, February 18, 2021 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| Wednesday, February 17, 2021 | ASSIGNED TO LIE |
| Thursday, February 11, 2021 | TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED |
| Thursday, October 1, 2020 | NOTIFICATION OF LETTER OF SUSPENSION E-MAILED |
| Thursday, October 1, 2020 | LETTER OF SUSPENSION E-MAILED |
| Thursday, October 1, 2020 | SUSPENSION LETTER WRITTEN |
| Friday, September 11, 2020 | TEAS/EMAIL CORRESPONDENCE ENTERED |
| Friday, September 11, 2020 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| Friday, September 4, 2020 | TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED |
| Tuesday, August 18, 2020 | NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED |
| Tuesday, August 18, 2020 | INQUIRY TO SUSPENSION E-MAILED |
| Tuesday, August 18, 2020 | SUSPENSION INQUIRY WRITTEN |
| Tuesday, August 4, 2020 | SUSPENSION CHECKED - TO ATTORNEY FOR ACTION |
| Thursday, January 9, 2020 | NOTIFICATION OF LETTER OF SUSPENSION E-MAILED |
| Thursday, January 9, 2020 | LETTER OF SUSPENSION E-MAILED |
| Thursday, January 9, 2020 | SUSPENSION LETTER WRITTEN |
| Thursday, December 26, 2019 | TEAS/EMAIL CORRESPONDENCE ENTERED |
| Thursday, December 26, 2019 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| Thursday, December 19, 2019 | ASSIGNED TO LIE |
| Monday, December 16, 2019 | TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED |
| Saturday, June 15, 2019 | NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED |
| Saturday, June 15, 2019 | INQUIRY TO SUSPENSION E-MAILED |
| Saturday, June 15, 2019 | SUSPENSION INQUIRY WRITTEN |
| Tuesday, June 11, 2019 | SUSPENSION CHECKED - TO ATTORNEY FOR ACTION |
| Tuesday, November 20, 2018 | NOTIFICATION OF LETTER OF SUSPENSION E-MAILED |
| Tuesday, November 20, 2018 | LETTER OF SUSPENSION E-MAILED |
| Tuesday, November 20, 2018 | SUSPENSION LETTER WRITTEN |
| Saturday, November 10, 2018 | TEAS/EMAIL CORRESPONDENCE ENTERED |
| Friday, November 9, 2018 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| Friday, November 9, 2018 | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
| Wednesday, May 9, 2018 | NOTIFICATION OF NON-FINAL ACTION E-MAILED |
| Wednesday, May 9, 2018 | NON-FINAL ACTION E-MAILED |
| Wednesday, May 9, 2018 | NON-FINAL ACTION WRITTEN |
| Wednesday, May 2, 2018 | ASSIGNED TO EXAMINER |
| Thursday, February 8, 2018 | PRELIMINARY/VOLUNTARY AMENDMENT - ENTERED |
| Wednesday, February 7, 2018 | ASSIGNED TO LIE |
| Saturday, February 3, 2018 | NOTICE OF DESIGN SEARCH CODE E-MAILED |
| Friday, February 2, 2018 | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED |
| Tuesday, January 30, 2018 | TEAS VOLUNTARY AMENDMENT RECEIVED |
| Thursday, January 25, 2018 | NEW APPLICATION ENTERED |